Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Dotmatics, while Willkie Farr & Gallagher LLP advised Insightful Science on the deal. Insightful Science, a leading software provider serving the global...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised the initial purchasers on the deal. Rapid7, Inc. (Nasdaq: RPD) announced the Rule 144A offering of $525 million principal amount of its 0.25% Convertible...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised the initial purchasers on the deal. Everbridge, Inc. (“Everbridge”) issued an aggregate of $375 million principal amount of its 0% Convertible Senior Notes...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised the initial purchasers on the deal. Cutera, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Stifel, Nicolaus & Company,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised ElevateBio on the deal. ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced it...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised the initial purchasers on the deal. MannKind Corporation (the “Company”) completed its previously announced private offering (the “Offering”) of $200.0 million aggregate...
You must be a Standard 1 Year member to access this content.
